Green Hill HealthCare Communications, LLC

SHERPA: Unknown

People

  1. Paik
    Paik
  2. Dunn
    Dunn
  3. Makker
    Makker
  4. Yu
    Yu

Groups

  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (4)
  4. Center for Hematologic Malignancies (1)
  5. GDMT, Medicine (1)
  6. Gynecologic Medicine Service (1)
  7. Gynecology Disease Management Team (1)
  8. Head and Neck Service (1)
  9. Hematologic Malignancies, Division of (1)
  10. Lymphoma (1)
Search Within
  1. "Journal of Oncology Navigation & Survivorship"
Formats
  1. Meeting Abstract (8)
  2. Review (1)
Groups
  1. Department of Medicine (7)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (4)
  4. Center for Hematologic Malignancies (1)
  5. GDMT, Medicine (1)
  6. Gynecologic Medicine Service (1)

More Groups

People
  1. Paul Paik (2)
  2. Helena Yu (1)
  3. Kathleen Meade (1)
  4. Krysten Soldan (1)
  5. Lara Dunn (1)
  6. Matthew Hellmann (1)

More People

Years
  1. 2023 (4)
  2. 2022 (2)
  3. 2020 (2)
  4. 2018 (1)
Publications
  1. Journal of Oncology Navigation & Survivorship (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mosunetuzumab monotherapy demonstrates durable efficacy and manageable safety in patients with relapsed/refractory follicular lymphoma and ≥2 prior therapies: Updated results from a pivotal phase 2 study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • ctDNA dynamics, prognostic markers, and mechanisms of resistance in tepotinib-treated MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Meeting Abstract

    Xiuning, L.; Garassino, M. C.; Ahn, M . J.; Felip, E.; Cortot, A. B.; Hiroshi, S.; Mazières, J.; Thomas, M.; Viteri, S.; Conte, P.; more...
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • Patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01
    Meeting Abstract

    Yu, H. A.; Yasushi, G.; Hidetoshi, H.; Felip, E.; Chih-Hsin Yang, J.; Reck, M.; Yoh, K.; Lee, S. H.; Paz-Ares, L.; Besse, B.; more...
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • An integrative education program for patients with renal-cell carcinoma and their caregivers: A scoping review
    Review

    Carlos, M.; Meade, K.; Henderson, J.; Gentry, E.
    Journal of Oncology Navigation & Survivorship (2023)

    Fulltext@MSK | Save
  • Primary analysis of phase 2 results for cemiplimab in patients with mBCC who progressed on or were intolerant to hedgehog inhibitors
    Meeting Abstract

    Lewis, K. D.; Peris, K.; Sekulic, A.; Stratigos, A. J.; Dunn, L.; Eroglu, Z.; Chang, A. L. S.; Migden, M. R.; Yoo, S. K.; Mohan, K.; more...
    Journal of Oncology Navigation & Survivorship (2022)

    Fulltext@MSK | Save
  • Intracranial activity of tepotinib in patients with MET Exon 14 (METex14) skipping non-small-cell lung cancer (NSCLC) enrolled in VISION
    Meeting Abstract

    Hill, R.; Leighl, N.; Bestvina, C.; Patel, J.; Le, X.; Veillon, R.; Anderson, I.; Demedts, I.; Garassino, M. C.; Mazières, J.; more...
    Journal of Oncology Navigation & Survivorship (2022)

    Fulltext@MSK | Save
  • Characterization and management of adverse reactions in patients with endometrial carcinoma receiving lenvatinib plus pembrolizumab (Study 111/KEYNOTE-146): Nurse roles in patient education and adverse-reaction management
    Meeting Abstract

    Soldan, K.; Johns, C.; Taylor, M. H.; Gillis, K.; Orlowski, R.; Min, R.; Makker, V.
    Journal of Oncology Navigation & Survivorship (2020)

    Fulltext@MSK | Save
  • COVID: An unexpected barrier to care
    Meeting Abstract

    Sales, R.
    Journal of Oncology Navigation & Survivorship (2020)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab + ipilimumab vs platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Gerber, D. E.; Reck, M.; Hellmann, M. D.; Paz-Ares, L.; Borghaei, H.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Ramalingam, S. S.
    Journal of Oncology Navigation & Survivorship (2018)

    Fulltext@MSK | Save

    • Green Hill HealthCare Communications, LLC – authorized name for: